Relapsed/Refractory Multiple Myeloma
Conditions
Brief summary
An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma
Interventions
DRUGIBI346
IBI346 Antibody and IBI346 CAR-T cell injection
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
The First Affiliated Hospital of Soochow University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. According to the multiple myeloma diagnostic criteria of the International Myeloma Working Group (IMWG), there is the initial diagnosis of multiple myeloma. 2. Subjects must have previously received at least 3 anti-myeloma regimens. Subjects must have documented disease progression (according to IMWG criteria) during or within 12 months of completing their last anti-myeloma regimen prior to study entry; and prior regimens must have included proteasome inhibitor (PI) and immunomodulatory drug (IMiD). 3. Measurable disease as defined by the protocol 4. ECOG score is 0 or 1. 5. Expected survival time ≥12 weeks.
Exclusion criteria
1. Patients suffering from graft-versus-host disease (GVHD) or requiring immunosuppressants drugs. 2. Patients who received autologous hematopoietic stem cell transplantation (ASCT) or prior allogeneic hematopoietic stem cell transplantation (ALLo-HSCT) within 12 weeks prior to mononuclear cell collection. 3. No unmobilized mononuclear cells can be collected for CAR T cell production. 4. Screening subjects who were receiving systemic steroids during the previous 7 days or who were determined by the investigator to require long-term systemic steroid use during treatment (except for inhaled or topical use, except at doses \< 10mg/ day). 5. Patients with a history of hypertension that cannot be controlled by medication (blood pressure ≥140/90 mmHg).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose limiting toxicity (DLT) | 21 days post IBI346 administration |
| Incidence and severity of adverse events: Proportion of subjects with treatment-related adverse events assessed by NCI-CTCAE v5.0 criteria | 2 years post IBI346 administration |
| Presence or absence of replication-competent lentivirus (RCL) | Baseline up to 15 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 2 years post IBI346 administration | OS is measured from the date of the initial administration of IBI346 to the date of the subject's death. |
| Pharmacokinetics parameters of IBI346 cells -Maximum CAR level in blood (Cmax) | 2 years post IBI346 administration | — |
| Pharmacokinetics parameters of IBI346 cells -Time to peak CAR level in blood (Tmax) | 2 years post IBI346 administration | — |
| Pharmacokinetics parameters of IBI346 cells - Area under the curve of the CAR level in blood (AUC) | 2 years post IBI346 administration | — |
| Pharmacokinetics parameters of IBI346 antibody- Peak Plasma Concentration (Cmax) | 2 years post IBI346 administration | — |
| Objective Response Rate (ORR) | 3 months post IBI346 administration | Number of patients with a best response of either complete response, stringent complete response, very good partial response or partial response, assessed using modified International Myeloma Working Group response criteria（2016） |
| Pharmacokinetics parameters of IBI346 antibody- clearance (CL) | 2 years post IBI346 administration | — |
| Pharmacokinetics parameters of IBI346 antibody- half-life (t1/2) | 2 years post IBI346 administration | — |
| Positive rate of human anti-P329G CAR antibody | 2 years post IBI346 administration | — |
| Positive rate of anti-drug antibody (ADA) of P329G BCMA antibody | 2 years post IBI346 administration | — |
| Pharmacokinetics parameters of IBI346 antibody- Area under the plasma concentration versus time curve (AUC) | 2 years post IBI346 administration | — |
| Duration of Response (DOR) | 2 years post IBI346 administration | DOR will be calculated among responders (with a PR or better response) from the date of initial response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria (2016). |
| Progression-free Survival (PFS) | 2 years post IBI346 administration | PFS defined as time from date of initial administration of IBI346 to date of first disease progression according to IMWG criteria (2016), or death due to any cause, whichever occurs first. |
Countries
China
Outcome results
None listed